Epalrestat

Epalrestat is an aldose reductase inhibitor.Aldose reductase reduses glucose to sorbitol. Epalrestat inhibited high glucose-mediated neutrophil?endothelial cell adhesion and expression of endothelial adhesion molecules not only through inhibition of a PKC-dependent pathway, but also through increased endothelial NO production. Long-term treatment with epalrestat is well tolerated and can effectively delay the progression of diabetic neuropathy and ameliorate the associated symptoms of the disease, particularly in subjects with good glycemic control and limited microangiopathy.